Algernon Pharmaceuticals Inc. C.AGN

Positive results from full set of phase 2a ifenprodil trials

[biggonads]

AGN reports positive results from the full set of their Phase 2a trials evaluating Ifenprodil to treat IPF and chronic cough including statistically significant improvements in measures of cough. This full set follows up the previously announced positive results from top line data reported in mid July. As a result of the final results, AGN will present the data to the U.S FDA, including applying for orphan designation, the filing of a pre-IND application for a Phase 2b IPF with cough trial, and an application for Breakthrough Therapy designation. https://www.globenewswire.com/news-release/2022/09/01/2508382/0/en/Algernon-Pharmaceuticals-Reports-Positive-Results-from-Full-Data-Set-of-its-Phase-2-Study-of-Ifenprodil-for-IPF-and-Chronic-Cough.html